|
Triclabendazole
|
DB12245 |
[Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food.
Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use.
This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452]] |
|
Aluminium nicotinate
|
DB13576 |
|
|
Allobarbital
|
DB13577 |
|
|
Inclacumab
|
DB12246 |
[Inclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.] |
|
Metabutethamine
|
DB13578 |
|
|
AZD-4547
|
DB12247 |
[AZD4547 has been used in trials studying the treatment of Cancer, LYMPHOMA, Gastric Cancer, Adenocarcinoma, and Solid Neoplasm, among others.] |
|
Mepixanox
|
DB13579 |
|
|
Tulobuterol
|
DB12248 |
[Tulobuterol has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.] |
|
TAK-733
|
DB12241 |
[TAK-733 has been used in trials studying the treatment of Advanced Metastatic Melanoma, Advanced Nonhematologic Malignancies, and Advanced Non-hematologic Malignancies.] |
|
Emylcamate
|
DB13572 |
|
|
Acefylline
|
DB13573 |
|
|
AZD-7762
|
DB12242 |
[AZD7762 has been investigated for the treatment of Cancer, Solid Tumors, and Advanced Solid Malignancies.] |
|
Heptaminol
|
DB13574 |
|
|
Edaravone
|
DB12243 |
[Edaravone is a free radical scavenger approved in May, 2017 for the treatment of amyotrophic lateral scleorosis (ALS). Clinical studies showed that the treatment attenuated deterioration of the disease when compared to placebo. It has been previously investigated for the treatment of ischemic stroke, reperfusion Injury, and myocardial Infarction as it possesses antioxidant and anti-apoptotic properties. Being a low molecular weight molecule with good water and lipid-soluble properies, it is therapeutically advantageous in crossing the blood-brain barrier to mediate nootropic and neuroprotective effects. Oral formulation of edaravone is currently under development.] |
|
Bietaserpine
|
DB13575 |
|
|
CP-601927
|
DB12244 |
[CP-601,927 has been used in trials studying the basic science and treatment of Major Depressive Disorder.] |
|
Oxidized cellulose
|
DB13570 |
|
|
Pentamycin
|
DB13571 |
|
|
Polatuzumab vedotin
|
DB12240 |
[Polatuzumab vedotin is a CD79b specific antibody conjugated to the antineoplastic agent monomethyl auristatin E.[Label] This medication was granted accelerated FDA approval on 10 June 2019.[L6658]] |
|
Imipenem
|
DB01598 |
[Imipenem is a semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains.[label] It is stable to many beta-lactamases. Similar compounds include [meropenem], known for having greater activity against Gram negative bacteria, and the newer [ertapenem] which exhibits a longer half-life due to increased binding to plasma proteins.[A15389] Imipenem is commonly used in combination with [cilastatin] and is now available in a triple-drug product with cilastatin and [relebactam] which was recently approved by the FDA. Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]] |
